Image de couverture de livre

Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Paolo Mannelli
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Addiction
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
par: Sandra A. Springer
Publié: (2024)

A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine
par: Charles Deng, et autres
Publié: (2025)

Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review
par: Emmert Roberts, et autres
Publié: (2026)

Evaluating the optimal duration of medication treatment for opioid use disorder
par: Corey J. Hayes, et autres
Publié: (2026)

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
par: Gary J. Young, et autres
Publié: (2024)

Dose‐specific clinical outcomes in patients with opioid use disorder treated with 24–32 mg/day of buprenorphine
par: Julia D’Agata Mount, et autres
Publié: (2024)

Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals
par: Jake R. Morgan, et autres
Publié: (2024)

Commentary on Qeadan et al .: Leveraging opportunities to expand the substance use disorder treatment arsenal
par: Ty S. Schepis
Publié: (2024)

Navigating pregnancy and addiction recovery: Patient perspectives on perinatal care interventions for women with opioid use disorder in Kentucky, USA
par: Hilary L. Surratt, et autres
Publié: (2026)

Questioning methadone split‐dosing for analgesia among hospitalized patients with opioid use disorder
par: Dale Terasaki, et autres
Publié: (2024)

Commentary on Stam et al .: The substantial and dynamic contribution of opioid potency to total overdose risk
par: Phillip O. Coffin
Publié: (2024)

Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada
par: Jenna Langlois, et autres
Publié: (2024)

Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
par: Nadine Ezard, et autres
Publié: (2025)

Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
par: Payel J. Roy, et autres
Publié: (2025)

Evaluating comparative effect of non‐pharmacological interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta‐analysis
par: Bei Lv, et autres
Publié: (2026)

Empirically contrasting urine drug screening‐based opioid use disorder treatment outcome definitions
par: Laura Brandt, et autres
Publié: (2024)

Commentary on Dennett et al .: When heat and the opioid epidemic collide ‐ implications for climate‐resilient public health strategies
par: Tarik Benmarhnia
Publié: (2025)

Commentary on Bade et al.: Threat of nitazenes and other potent synthetic opioids—Is Europe prepared? Time to respond and to learn
par: Isabelle Giraudon, et autres
Publié: (2025)

Commentary on Ezard et al.: Agonist‐based medications for stimulant use disorder—Distinguishing their true colours
par: Vitor S. Tardelli, et autres
Publié: (2025)

Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder – an urgent path forward
par: Adam Bisaga
Publié: (2025)

Commentary on Östh et al.: Sensor‐based approaches to inform alcohol interventions – beyond BAC
par: Brian Suffoletto
Publié: (2025)

Development and evaluation of a machine learning model to predict acute care for opioid use disorder among Medicaid enrollees engaged in a community‐based treatment program
par: Lingshu Xue, et autres
Publié: (2025)

Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
par: Brenda Carolina Guerra‐Alejos, et autres
Publié: (2024)

Addressing tobacco use in the context of opioid use disorder: A systematic review of smoking cessation interventions
par: Suprit Parida, et autres
Publié: (2026)

Comment on Domzaridou et al .: Recognising the complexities of co‐prescriptions and lifestyle factors in opioid agonist treatment
par: Adam Bakker, et autres
Publié: (2024)

Commentary on Nieto et al .: The heterogeneity of drug craving and considerations as a treatment endpoint
par: Justin C. Strickland, et autres
Publié: (2026)

Commentary on Aubin et al.: Could combination medication approaches target mental health comorbidity in the context of alcohol use disorder?
par: Shalini Arunogiri, et autres
Publié: (2024)

Contingency management as a maintenance intervention in the long‐term treatment of substance use disorders
par: Forrest Toegel, et autres
Publié: (2024)

Commentary on Giné et al .: The hidden face of overdose: Gender inequities along the continuum of care
par: Patrizia Carrieri, et autres
Publié: (2025)

Potential health impacts of comprehensive access to opioid use disorder treatment in United States correctional facilities: A synthetic analysis
par: Jake J. Smith, et autres
Publié: (2025)

Commentary on Yang et al.: The need for a renewed focus on identifying and responding to chronic pain among people with substance use disorders
par: Gabrielle Campbell, et autres
Publié: (2024)

Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience
par: Julien Cabé, et autres
Publié: (2026)

Primary care's most pressing needs to address opioid use disorder: A qualitative study
par: Elise A. Robertson, et autres
Publié: (2026)

Do we need clinical trials of high dose stimulant agonist treatment for stimulant use disorders?
par: Wayne Hall, et autres
Publié: (2024)

Systematic review of patient‐reported outcome measures for opioid use disorder recovery
par: Jarratt D. Pytell, et autres
Publié: (2025)

Effectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: A systematic review and meta‐analysis
par: Monika Halicka, et autres
Publié: (2025)

Commentary on Amin‐Esmaeili et al .: Non‐abstinence outcomes in stimulant clinical trials—Why deny improvement?
par: Vítor S. Tardelli
Publié: (2024)

Academic detailing is effective at altering clinician practice and patient outcomes for opioid use disorder
par: Jonathan Zhang, et autres
Publié: (2026)

Telemedicine‐assisted buprenorphine induction versus standard of care: A randomized controlled non‐inferiority trial
par: Harpreet S. Dhillon, et autres
Publié: (2025)

Variations in US county‐level trends in buprenorphine use, 2018–2022
par: Taylor W. Lefler, et autres
Publié: (2025)